These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29571585)

  • 21. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
    Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
    J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer.
    Fang Z; Dai W; Wang X; Chen W; Shen C; Ye G; Li L
    Tumour Biol; 2016 Jun; 37(6):8075-82. PubMed ID: 26715266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlations of Foxo3 and Foxo4 expressions with clinicopathological features and prognosis of bladder cancer.
    Wang Y; Kang XL; Zeng FC; Xu CJ; Zhou JQ; Luo DN
    Pathol Res Pract; 2017 Jul; 213(7):766-772. PubMed ID: 28554751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer.
    van de Putte EEF; Bosschieter J; van der Kwast TH; Bertz S; Denzinger S; Manach Q; Compérat EM; Boormans JL; Jewett MAS; Stoehr R; van Leenders GJLH; Nieuwenhuijzen JA; Zlotta AR; Hendricksen K; Rouprêt M; Otto W; Burger M; Hartmann A; van Rhijn BWG
    BJU Int; 2018 Dec; 122(6):978-985. PubMed ID: 29637669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute.
    Miyake M; Gotoh D; Shimada K; Tatsumi Y; Nakai Y; Anai S; Torimoto K; Aoki K; Tanaka N; Konishi N; Fujimoto K
    Int J Urol; 2015 Jun; 22(6):541-7. PubMed ID: 25857336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.
    van Kessel KE; van de Werken HJ; Lurkin I; Ziel-van der Made AC; Zwarthoff EC; Boormans JL
    PLoS One; 2017; 12(3):e0174039. PubMed ID: 28319171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.
    Martínez-Fernández M; Dueñas M; Feber A; Segovia C; García-Escudero R; Rubio C; López-Calderón FF; Díaz-García C; Villacampa F; Duarte J; Gómez-Rodriguez MJ; Castellano D; Rodriguez-Peralto JL; de la Rosa F; Beck S; Paramio JM
    Oncotarget; 2015 Dec; 6(39):42258-75. PubMed ID: 26517683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer.
    Patry G; Hovington H; Larue H; Harel F; Fradet Y; Lacombe L
    Int J Cancer; 2008 Apr; 122(7):1592-7. PubMed ID: 18058798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors of 'high-grade' Ta bladder cancers according to the WHO 2004 classification: are these equivalent to 'high-risk' non-muscle-invasive bladder cancer?
    Gontero P; Gillo A; Fiorito C; Oderda M; Pacchioni D; Casetta G; Peraldo F; Zitella A; Tizzani A; Ricceri F
    Urol Int; 2014; 92(2):136-42. PubMed ID: 24080613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results.
    Mares J; Szakacsova M; Soukup V; Duskova J; Horinek A; Babjuk M
    Neoplasma; 2013; 60(3):295-301. PubMed ID: 23452234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: a novel approach using peptide nucleic acid-mediated, real-time PCR clamping.
    Kim EJ; Yan C; Ha YS; Jeong P; Yi Kim I; Moon SK; Choi YH; Kim WJ
    Urol Oncol; 2012 Sep; 30(5):673-9. PubMed ID: 20884250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study.
    Kobayashi S; Fujii Y; Koga F; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
    Urol Oncol; 2014 Jan; 32(1):38.e29-36. PubMed ID: 23702087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.
    Klatte T; Seligson DB; Rao JY; Yu H; de Martino M; Kawaoka K; Wong SG; Belldegrun AS; Pantuck AJ
    Cancer; 2009 Apr; 115(7):1448-58. PubMed ID: 19195047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer.
    Kang HW; Seo SP; Jeong P; Ha YS; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
    Oncol Lett; 2017 Aug; 14(2):2468-2474. PubMed ID: 28781684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
    Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
    Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study.
    Dyrskjøt L; Zieger K; Real FX; Malats N; Carrato A; Hurst C; Kotwal S; Knowles M; Malmström PU; de la Torre M; Wester K; Allory Y; Vordos D; Caillault A; Radvanyi F; Hein AM; Jensen JL; Jensen KM; Marcussen N; Orntoft TF
    Clin Cancer Res; 2007 Jun; 13(12):3545-51. PubMed ID: 17575217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.